HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole

Author's Avatar
Jul 20, 2018
Article's Main Image

Access to UCONN's technology could create the potential for HPPI to expand its pipeline of clinical stage itraconazole-based cancer treatments

PR Newswire